- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02730299
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion.
A major drawback of Umbilical Cord Blood (UCB) is the low stem cell dose available for transplantation, compared to mobilized peripheral blood (PB) or bone marrow. This low stem cell dose can compromise the chances of engraftment and contributes to delayed kinetics of neutrophil and platelet recovery, as well as other transplant outcomes.
The aim of ex vivo expansion of cord blood is to provide a graft with sufficient numbers of cells that have rapid and robust in vivo neutrophil and platelet producing potential to enable successful transplantation.
NiCord® is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic cells from one entire unit of UCB. NiCord® utilizes the small molecule nicotinamide (NAM), as an epigenetic approach to inhibit differentiation and to increase the migration, bone marrow (BM) homing and engraftment efficiency of Hematopoietic Progenitor Cells (HPC) expanded in ex vivo cultures. The chief aim of the study is to compare the safety and efficacy of NiCord® single ex-vivo expanded cord blood unit transplantation to unmanipulated cord blood unit transplantation in patients with hematological malignancies following conditioning therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rio De Janeiro, Brazil, 20230-130
- Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
-
São Paulo, Brazil
- Hospital Israelita Albert Einstein
-
São Paulo, Brazil, 05403-010
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Pediatrics
-
São Paulo, Brazil, 05403-010
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
-
São Paulo, Brazil, 14048-900
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
-
-
-
-
-
Paris, France, 75019
- Robert Debre
-
-
-
-
-
Haifa, Israel
- Rambam
-
Jerusalem, Israel
- Hadassah Medical Center
-
Petach Tikva, Israel
- Rabin Medical Center, Beilinson Hospital
-
Tel Aviv, Israel
- Dana-Dwek Children's Hospital, Tel-Aviv Sourasky Medical Center
-
Tel Aviv, Israel
- Tel-Aviv Sourasky Medical Center
-
Tel HaShomer, Israel
- Chaim Sheba Medical Center, The Edmond and Lily Safra Children's hospital
-
-
-
-
-
Florence, Italy, 50134
- Careggi University Hospital
-
Rome, Italy, 00165
- Ospedale Pediatrico Bambino Gesù
-
-
-
-
-
Utrecht, Netherlands, 3503 AB
- University Medical Center Utrecht
-
Utrecht, Netherlands, 3584 CS
- Prinses Maxima Centrum voor Kinderoncologie B.V.
-
-
-
-
-
Lisbon, Portugal, 1099-023
- Instituto Portugues de Oncologia de Lisboa Francisco Gentil
-
-
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
Singapore, Singapore, 119074
- National University Cancer Institute
-
-
-
-
-
Barcelona, Spain
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spain, 08035
- University Hospital Vall d'Hebron
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron pediatrics
-
Barcelona, Spain, 08908
- ICO Bellvitge
-
Barcelona, Spain, 08950
- Sant Joan de Deu
-
Sevilla, Spain
- Hospital Universitario Virgen del Rocio
-
Valencia, Spain, 46009
- Hospital Universitario La Fe
-
Valencia, Spain
- Hospital Universitario y Politécnico La Fe (pediatric)
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Queen Elizabeth Hospital
-
Leeds, United Kingdom, LS9 7TF
- St James Hospital
-
Manchester, United Kingdom, M13 9WL
- Manchester University NHS Foundation Trust
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- The Royal Marsden NHS Foundation Trust
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
Los Angeles, California, United States, 91010
- City of Hope
-
Palo Alto, California, United States
- Stanford University Cancer Institute
-
San Diego, California, United States, 92093
- UC San Diego Moores Cancer Center
-
-
Colorado
-
Denver, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Illinois
-
Evanston, Illinois, United States, 60208
- Northwestern University
-
Maywood, Illinois, United States, 60153
- Loyola University, Cardinal Bernardin Cancer Center
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- University of Kansas Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- The University of Maryland Medicine Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Michigan
-
Detroit, Michigan, United States
- Henry Ford Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Masonic Cancer Center
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Rutgers Cancer Institute of New Jersey
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Children's
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- West Cancer Clinic
-
-
Texas
-
Dallas, Texas, United States, 75235
- Children's Medical Center of Dallas
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Applicable disease criteria
- Patients must have one or two partially HLA-matched CBUs
- Back-up stem cell source
- Adequate Karnofsky/Lansky Performance score
- Sufficient physiological reserves
- Signed written informed consent
Exclusion Criteria:
- HLA-matched donor able to donate
- Prior allogeneic HSCT
- Other active malignancy
- Active or uncontrolled infection
- Active/symptoms of central nervous system (CNS) disease
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NiCord® (omidubicel)
NiCord® is a cryopreserved stem/progenitor cell based product comprised of:
Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation. |
|
Active Comparator: Unmanipulated CBU(s)
|
Cord blood unit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Neutrophil Engraftment
Time Frame: post-transplant up to 42 days
|
The time to engraftment of neutrophils >500/μl was defined as per Center for International Blood and Marrow Transplant Research (CIBMTR) standards, requiring donor chimerism for neutrophil engraftment.
|
post-transplant up to 42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First Grade 2/3 Bacterial or Invasive Fungal Infections by 100 Days Following Transplantation
Time Frame: 100 days post-transplant
|
First Bacterial Infection Grades 2-3 or Invasive Fungal Infection by 100 Days following Transplantation for the Intent to Treat Population
|
100 days post-transplant
|
Days Alive and Out of Hospital in the First 100 Days Post-transplantation
Time Frame: 100 days post-transplantation
|
Days alive and out of hospital in the first 100 Days post-transplantation for the Intent to Treat Population
|
100 days post-transplantation
|
Number of Participants With Platelet Engraftment by 42 Days Post-transplantation
Time Frame: 42 days post-transplantation
|
Platelet engraftment defined as the first day of a minimum of three consecutive measurements on different days such that the patient has achieved a platelet count > 20 × 10^9/L with no platelet transfusions during the preceding seven days (counting day of engraftment as one of the preceding seven days) for the Intent to Treat Population
|
42 days post-transplantation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mitchell Horwitz, MD, Duke University
Publications and helpful links
General Publications
- Del Pozo Martin Y. 47th Annual Meeting of the EBMT. Lancet Haematol. 2021 May;8(5):e317-e318. doi: 10.1016/S2352-3026(21)00104-6. Epub 2021 Mar 31. No abstract available.
- Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, Rezvani AR, Karris NA, McGuirk J, Valcarcel D, Schiller GJ, Lindemans CA, Hwang WYK, Koh LP, Keating A, Khaled Y, Hamerschlak N, Frankfurt O, Peled T, Segalovich I, Blackwell B, Wease S, Freedman LS, Galamidi-Cohen E, Sanz G. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021 Oct 21;138(16):1429-1440. doi: 10.1182/blood.2021011719.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Neoplasms by Site
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Precancerous Conditions
- Leukemia, Lymphoid
- Chronic Disease
- Neoplasms
- Lymphoma
- Myelodysplastic Syndromes
- Hematologic Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Preleukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Other Study ID Numbers
- GC P#05.01.020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on NiCord® (omidubicel)
-
Gamida Cell ltdCompletedPatients Transplanted With NiCord/CordIn (Omidubicel)United States, Singapore, Spain, Netherlands
-
Gamida Cell ltdActive, not recruitingHematological MalignanciesUnited States
-
Gamida Cell ltdCompletedTransplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HMHematological Malignancies | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS)United States, Singapore, Spain, Netherlands, Italy
-
Gamida Cell ltdCompletedNon-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Hodgkin's Disease | Acute Myelogenous Leukemia (AML)United States
-
Gamida Cell ltdCompletedSickle Cell Disease & ThalassemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingMyelodysplastic Syndrome (MDS) | Severe Aplastic Anemia | Hypo-Plastic MDSUnited States
-
Chong Kun Dang PharmaceuticalCompleted
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China